RAFFAELE DE LUCA

Dr. RAFFAELE DE LUCA

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Cancer
Verified
Journal Article
Open access
Rosa DivellaRosa Divella
Rosa Divella
RLRAFFAELE DE LUCA
RAFFAELE DE LUCA
IAInes Abbate
Ines Abbate
ENEmanuele Naglieri
Emanuele Naglieri
ADAntonella Daniele
Antonella Daniele
Adipose tissue in addition to its ability to keep lipids is now recognized as a real organ with both metabolic and endocrine functions. Recent studies demonstrated that in obese animals is established a status of adipocyte hypoxia and in this hypoxic state interaction between adipocytes and stromal vascular cells contribute to tumor development and progression. In several tumors such as breast, colon, liver and prostate, obesity represents a poor predictor of clinical outcomes. Dysfunctional adipose tissue in obesity releases a disturbed profile of adipokines with elevated levels of pro-inflammatory factors and a consequent alteration of key signaling mediators which may be an active local player in establishing the peritumoral environment promoting tumor growth and progression. Therefore, adipose tissue hypoxia might contribute to cancer risk in the obese population. To date the precise mechanisms behind this obesity-cancer link is not yet fully understood. In the light of information provided in this review that aims to identify the key mechanisms underlying the link between obesity and cancer we support that inflammatory state specific of obesity may be important in obesity-cancer link.

1 February 2018 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
KPKarol Polom
Karol Polom
Luigi MaranoLuigi Marano
Luigi Marano
DMD. Marrelli
D. Marrelli
RLRAFFAELE DE LUCA
RAFFAELE DE LUCA
giandomenico roviellogiandomenico roviello
giandomenico roviello
FRF. Roviello
F. Roviello

24 November 2021 in Colorectal Disease
Verified
Journal Article
Open access
PDF file
MDMaurizio Degiuli
Maurizio Degiuli
UEUgo Elmore
Ugo Elmore
RLRAFFAELE DE LUCA
RAFFAELE DE LUCA
PNPaola De Nardi
Paola De Nardi
MTMariano Tomatis
Mariano Tomatis
TGThe Italian Society of Surgical Oncology – Colorectal Cancer Network Collaborative Group
The Italian Society of Surgical Oncology – Colorectal Cancer Network Collaborative Group
Aim: Anastomotic leakage after restorative surgery for rectal cancer shows high morbidity and related mortality. Identification of risk factors could change operative planning, with indications for stoma construction. This retrospective multicentre study aims to assess the anastomotic leak rate, identify the independent risk factors and develop a clinical prediction model to calculate the probability of leakage.Methods: The study used data from 24 Italian referral centres of the Colorectal Cancer Network of the Italian Society of Surgical Oncology. Patients were classified into two groups, AL (anastomotic leak) or NoAL (no anastomotic leak). The effect of patient‐, disease‐, treatment‐ and postoperative outcome‐related factors on anastomotic leak after univariable and multivariable analysis was measured.Results: A total of 5398 patients were included, 552 in group AL and 4846 in group NoAL. The overall incidence of leaks was 10.2%, with a mean time interval of 6.8 days. The 30‐day leak‐related mortality was 2.6%. Sex, body mass index, tumour location, type of approach, number of cartridges employed, weight loss, clinical T stage and combined multiorgan resection were identified as independent risk factors. The stoma did not reduce the leak rate but significantly decreased leak severity and reoperation rate. A nomogram with a risk score (RALAR score) was developed to predict anastomotic leak risk at the end of resection.Conclusions: While a defunctioning stoma did not affect the leak risk, it significantly reduced its severity. Surgeons should recognize independent risk factors for leaks at the end of rectal resection and could calculate a risk score to select high‐risk patients eligible for protective stoma construction.

5 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
FFFrancesca De Felice
Francesca De Felice
SMSilvia Malerba
Silvia Malerba
VNValerio Nardone
Valerio Nardone
VSViola Salvestrini
Viola Salvestrini
NCnatale calomino
natale calomino
Luigi MaranoLuigi Marano
Luigi Marano
Introduction: Nutritional care is a cornerstone of cancer treatment, with the potential to significantly improve patient outcomes by addressing malnutrition and enhancing recovery. Despite growing awareness, the integration of evidence-based nutritional strategies into oncology remains inconsistent. Following a 2020 survey that highlighted critical gaps, the NutriOnc Research Group launched targeted initiatives to raise awareness and improve practices. This study reassesses progress in integrating nutritional care and identifies persistent challenges. Methods: A 29-question survey was conducted in 2024 among 73 early-career oncologists, surgeons, radiation oncologists, and nutrition specialists across Italy. Respondents provided insights into clinical nutrition program availability, multidisciplinary team composition, screening practices, and educational needs. Results: Encouraging advancements were noted, with 80.8% of respondents reporting the presence of clinical nutrition programs, compared to fewer structured efforts in 2020. However, only 26.0% included nutrition specialists in multidisciplinary teams, and barriers such as financial constraints, limited product availability, and the absence of trained professionals persisted. While 82.2% performed nutritional screening, variability in tools and practices highlighted the need for standardization. Strikingly, 98.6% expressed a strong demand for advanced education on clinical nutrition, emphasizing the need for innovative and accessible training programs. Conclusions: This study reveals a landscape of progress tempered by persistent inequities. To close the gap, oncology must embrace standardized protocols, expand access to trained nutrition specialists, and invest in educational initiatives. The findings offer actionable insights for transforming cancer care through nutrition, underscoring its potential to improve survival, quality of life, and overall treatment success.

1 March 2016 in Medicine
Verified
Journal Article
Open access
Luigi MaranoLuigi Marano
Luigi Marano
GPGiovanni Pallabazzer
Giovanni Pallabazzer
BSBiagio Solito
Biagio Solito
SSStefano Santi
Stefano Santi
APAlessio Pigazzi
Alessio Pigazzi
APAlberto Patriti
Alberto Patriti
To date very few studies with small sample size have compared peroral esophageal myotomy (POEM) with the current surgical standard of care, laparoscopic Heller myotomy (LHM), in terms of efficacy and safety, and no recommendations have been proposed.To investigate the efficacy and safety of POEM compared with LHM, for the treatment of achalasia.The databases of Pubmed, Medline, Cochrane, and Ovid were systematically searched between January 1, 2005 and January 31, 2015, with the medical subject headings (MeSH) and keywords "achalasia," "POEM," "per oral endoscopic myotomy," and "peroral endoscopic myotomy," "laparoscopic Heller myotomy" (LHM), "Heller myotomy."All types of study designs including adult patients with diagnosis of achalasia were selected. Studies that did not report the comparison between endoscopic and surgical treatment, experimental studies in animal models, single case reports, technical reports, reviews, abstracts, and editorials were excluded.The total number of included patients was 486 (196 in POEM group and 290 in LHM group).There were no differences between POEM and LHM in reduction in Eckardt score (MD = -0.659, 95% CI: -1.70 to 0.38, P = 0.217), operative time (MD = -0.354, 95% CI: -1.12 to 0.41, P = 0.36), postoperative pain scores (MD = -1.86, 95% CI: -5.17 to 1.44, P = 0.268), analgesic requirements (MD = -0.74, 95% CI: -2.65 to 1.16, P = 0.445), and complications (OR = 1.11, 95% CI: 0.5-2.44, P = 0.796). Length of hospital stay was significantly lower for POEM (MD = -0.629, 95% CI: -1.256 to -0.002, P = 0.049). There was a trend toward significant reduction in symptomatic gastroesophageal reflux rate in favors of LHM compared to POEM group (OR = 1.81, 95% CI: 1.11-2.95, P = 0.017).All included studied were not randomized. Furthermore all selected studies did not report the results of follow-up longer than 1 year and most of them included patients who were both treatment naive and underwent previous endoscopic or surgical interventions for achalasia.POEM represents a safe and efficacy procedure comparable to the safety profile of LHM for achalasia at a short-term follow-up. Long-term clinical trials are urgently needed.

22 December 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
RLRAFFAELE DE LUCA
RAFFAELE DE LUCA
LGLuca Gianotti
Luca Gianotti
PPPaolo Pedrazzoli
Paolo Pedrazzoli
OBOronzo Brunetti
Oronzo Brunetti
ARAlessandro Rizzo
Alessandro Rizzo
Riccardo CaccialanzaRiccardo Caccialanza
Riccardo Caccialanza